Anthony Pope

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

Santiago Ponce Aix, Tudor–Eliade Ciuleanu, Alejandro Navarro et al. · The Lancet Respiratory Medicine · 2022 · 120 citations · Full text

Medicine, Oncology, Pharmacology +11

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

Eric Lim, David Waller, Kelvin Lau et al. · The Lancet Respiratory Medicine · 2024 · 119 citations · Full text

Medicine, Oncology, Surgery +14

BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.

Sanjay Popat, Enriqueta Felip, Urania Dafni et al. · Journal of Clinical Oncology · 2024 · 13 citations · Full text

Medicine, Oncology, Pharmacology +17

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma

Krisztián Homicskó, Panagiota Zygoura, Maxim Norkin et al. · Journal for ImmunoTherapy of Cancer · 2023 · 11 citations · Full text

Life Sciences, Immunology, Oncology +17